Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors

Dec 19, 2022

Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2022

Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa

Dec 14, 2022

Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Dec 06, 2022

Checkpoint Therapeutics Announces Reverse Stock Split

Dec 05, 2022

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Dec 05, 2022

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 14, 2022

Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 14, 2022

Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 10, 2022

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 10, 2022
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...52
    Next

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2023 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap